论文部分内容阅读
评价肝动脉化疗栓塞合并ＬＡＫ／ＩＬ┐２灌注治疗原发性肝癌的初步疗效。方法不能切除的肝癌患者经肝动脉化疗栓塞后灌注自体ＬＡＫ细胞及ＩＬ┐２，并与单独行肝动脉化疗栓塞的不能切除肝癌患者比较其肿瘤大小，生活质量的变化及毒副反应。结果经肝动脉化疗栓塞合并ＬＡＫ／ＩＬ┐２灌注治疗的２２例肝癌有效率（ＣＲ＋ＰＲ）为１３．６％，包括１例完全缓解和２例部分缓解，而单独化疗栓塞对照组１７例中仅１例显示部分缓解（有效率５．９％）。化疗栓塞＋ＬＡＫ／ＩＬ┐２治疗组与单独化疗栓塞对照组中ＭＲ、ＳＤ、ＰＤ分别为５、１２、１例和１、１１、４例。治疗组中大多数病人生活质量改善或稳定，而对照组中生活质量则无提高。两组病人的毒副反应均较轻而短暂。结论经肝动脉化疗栓塞合并ＬＡＫ／ＩＬ┐２灌注治疗原发性肝癌疗效较优于单独肝动脉化疗栓塞治疗，原发性肝癌更有效的综合治疗方案有待进一步探索
To evaluate the primary efficacy of hepatic arterial chemoembolization combined with LAK/IL┐2 infusion for primary hepatocellular carcinoma. Methods The patients with unresectable liver cancer were treated with transcatheter arterial chemoembolization and perfused with autologous LAK cells and IL-2. The tumor size, quality of life, and toxicities were compared with those of unresectable liver cancer patients undergoing hepatic arterial chemoembolization. Results The effective rate (CR+PR) of liver cancer in 13 patients treated with hepatic arterial chemoembolization combined with LAK/IL 2 infusion was 13.6%, including one case of complete remission and two cases of partial remission, compared with only 17 cases of chemotherapy embolization alone in the control group. One case showed partial relief (effective rate 5.9%). In the chemoembolization+LAK/IL┐2 treatment group and the chemoembolization control group, MR, SD and PD were 5, 12, 1 and 1, 1 and 4, respectively. The quality of life of most patients in the treatment group improved or stabilized, while there was no improvement in the quality of life in the control group. The toxicity of the two groups of patients was mild and transient. Conclusion Transcatheter arterial chemoembolization combined with LAK/IL┐2 infusion is more effective than hepatic arterial chemoembolization in the treatment of primary liver cancer. A more effective comprehensive treatment plan for primary liver cancer needs further exploration.